| Literature DB >> 34114731 |
Saeed A Chowdhry1, Yeni Nieves-Malloure2, Mark Camardo2, Julie M Robertson2, Joshua Keys2.
Abstract
Oxidised regenerated cellulose (ORC)/collagen dressings help maintain physiologically moist wound environments conducive to wound healing. While evidence supporting ORC/collagen dressing use exists, comprehensive assessment is needed. This systematic review/meta-analysis evaluated the performance of ORC/collagen dressings compared with standard dressings. A systematic literature search was performed using PUBMED, EMBASE, and QUOSA Virtual Library. Published studies and conference abstracts were assessed between 1 January 1996 and 27 July 2020. Comparative studies in English completed by 31 December 2019, with a study population ≥10 were included. Patient demographics, wound healing, and protease concentrations were extracted. A random-effect model was used to assess the effect of ORC/collagen dressings. Twenty studies were included following removal of duplicates and articles not meeting inclusion criteria. A statistically significant effect in favour of ORC/collagen dressings was found for wound closure (P = 0.027) and percent wound area reduction (P = 0.006). Inconclusive evidence or limited reporting prevented assessment of time to complete healing, days of therapy, number of dressing applications, pain, matrix metalloproteinase, elastase, plasmin, and gelatinase concentration. Statistically significant increase in wound closure rates and percent wound area reduction were observed in patients receiving ORC/collagen dressings compared with standard dressings in this systematic review/meta-analysis.Entities:
Keywords: cellulose dressings; collagen dressings; matrix metalloproteinases; meta-analysis; wound healing
Mesh:
Substances:
Year: 2021 PMID: 34114731 PMCID: PMC8762558 DOI: 10.1111/iwj.13625
Source DB: PubMed Journal: Int Wound J ISSN: 1742-4801 Impact factor: 3.315
FIGURE 1PRISMA flowchart showing the literature search process. ORC, Oxidised regenerated cellulose
Characteristics of studies included in the meta‐analysis
| Study | Study type | Wound type | Number of patients | Population risk factors | Therapy used | Length of therapy (days, SD) | ||
|---|---|---|---|---|---|---|---|---|
| Treatment | Control | Treatment | Control | |||||
| Ambrosch 2006 | PC | Chronic ulcers | 25 | Not reported | ORC/collagen | SOC | 10‐14 | 10‐14 |
| Catalfamo 2013 | PC | Oral cavity wounds | 80 | Not reported | ORC/collagen | Gauze, hydrogen peroxide, iodopovidone | NR | NR |
| Chowdhry 2019 | RC | Donor site wounds | 59 | HTN, hyperlipidaemia, PVD, Obesity, COPD, CHF, CAD, asthma, atrial fibrillation | ORC/Collagen/Ag‐ORC | Film dressing | NR | NR |
| Cullen 2017 | RCT | VLU | 49 | Not reported | ORC/collagen/Ag‐ORC | SOC | NR | NR |
| Gottrup 2013 | RCT | DFU | 39 | Diabetes | ORC/collagen/Ag‐ORC | SOC | NR | NR |
| Griffin 2019 | RC | DFU | 844 | Arterial vascular disease, HTN, PVD, endovascular treatment | ORC/Collagen/Ag‐ORC | ECM; endoform natural dermal template | 21 (NR) | 21 (NR) |
| Kakagia 2007 | RCT | DFU | 34 | Not reported | ORC/collagen | Gravitational platelet separation system | 56 (NR) | 56 (NR) |
| Kloeters 2015 | RCT | PI | 33 | Not reported | ORC/collagen | Foam hydropolymer dressing | NR | NR |
| Lazaro‐Martinez 2007 | RCT | DFU | 38 | HTN, heart disease, PVD, amputation | ORC/collagen | SOC | 14 (NR) | 14 (NR) |
| Lobmann 2006 | PC | DFU | 33 | Not reported | ORC/collagen/Ag‐ORC | SOC | 8 (NR) | 8 (NR) |
| Lüedemann 2009 | PC | DFU | 21 | Not reported | ORC/collagen | SOC | NR | NR |
| Motzkau 2011 | RCT | DFU | 19 | Diabetes | ORC/collagen | Silicone wound contact layer | NR | NR |
| Nisi 2005 | RCT | PI | 80 | Not reported | ORC/collagen | Daily disinfection of the wound, gauze soaked in white Vaseline, and hydropolymer patch | NR | NR |
| Schmutz 2008 | RCT | VLU | 117 | Diabetes, vein thrombosis | ORC/collagen | Nano‐oligosaccharide factor | NR | NR |
| Smeets 2008 | RCT | VLU | 27 | Not reported | ORC/collagen | Hydrocolloid dressing | NR | NR |
| Snyder 2010 | RC | PI, DFU, surgical wounds, VLUs, infected wounds, trauma | 974 | Not reported | ORC/collagen | Gauze and saline | 38.6 (4.62) | NR |
| Ulrich 2011 | PC | DFU | 32 | Diabetes | ORC/collagen | Hydrocolloid dressing | NR | NR |
| Veves 2002 | RCT | DFU | 276 | Not reported | ORC/collagen | Moistened gauze | NR | NR |
| Vin 2002 | RCT | VLU | 73 | Hip arthrosis, knee arthrosis, diabetes, CHD, HTN | ORC/collagen | Non‐adherent silicone dressing | 65.9 (23.9) | 63.8 (25.2) |
| Wollina 2005 | CC | VLU | 40 | Not reported | ORC/collagen | Hydropolymer and hydrocolloid dressings | NR | NR |
Abbreviations: Ag, silver; CAD, coronary artery disease; CC, case–control study; CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DFU, diabetic foot ulcer; HTN, hypertension; NR, not reported; ORC, oxidised regenerated cellulose; PC, prospective cohort; PI, pressure injury; PVD, peripheral vascular disease; RC, retrospective cohort; RCT, randomised controlled trial; SD, standard deviation; VLU, venous leg ulcer.
Risk of bias within studies
| Study | Evidence level | Randomisation | Allocation masking | Blinding | Blinded outcomes assessments | Enrolled patients to number assessed | Results to defined endpoints |
|---|---|---|---|---|---|---|---|
| Ambrosch 2006 | 2 | High risk | Unclear | High risk | High risk | Low risk | Low risk |
| Catalfamo 2013 | 2 | High risk | Unclear | High risk | Unclear | Low risk | Low risk |
| Chowdhry 2019 | 3 | High risk | Unclear | High risk | High risk | Low risk | Low risk |
| Cullen 2017 | 1 | Low risk | Unclear | High risk | High risk | Low risk | Low risk |
| Gottrup 2013 | 1 | Low risk | Low risk | High risk | High risk | Low risk | Low risk |
| Griffin 2019 | 3 | High risk | Unclear | High risk | High risk | Low risk | Low risk |
| Kakagia 2007 | 1 | Low risk | Unclear | High risk | High risk | Low risk | Low risk |
| Kloeters 2015 | 1 | Low risk | Unclear | High risk | High risk | Low risk | Low risk |
| Lazaro‐Martinez 2007 | 1 | Low risk | Unclear | High risk | High risk | Low risk | Low risk |
| Lobmann 2006 | 2 | High risk | Unclear | High risk | Unclear | Low risk | Low risk |
| Luedemann 2009 | 2 | High risk | Unclear | High risk | Unclear | Low risk | Low risk |
| Motzkau 2011 | 1 | Low risk | Unclear | High risk | Unclear | Low risk | Low risk |
| Nisi 2005 | 1 | Low risk | Unclear | High risk | Unclear | Low risk | Low risk |
| Schmutz 2008 | 1 | Low risk | Unclear | High risk | High risk | Low risk | Low risk |
| Smeets 2008 | 1 | Low risk | Unclear | High risk | Unclear | Low risk | Low risk |
| Snyder 2010 | 3 | High risk | Unclear | High risk | Unclear | Low risk | Low risk |
| Ulrich 2011 | 2 | Unclear | Unclear | High risk | High risk | Low risk | Low risk |
| Veves 2002 | 1 | Low risk | Unclear | High risk | High risk | Low risk | Low risk |
| Vin 2002 | 1 | Low risk | Unclear | High risk | High risk | Low risk | Low risk |
| Wollina 2005 | 2 | High risk | Unclear | High risk | High risk | Low risk | Low risk |
FIGURE 2Funnel plot of studies included in the meta‐analysis. Each circle indicates a single study; solid lines indicate the 95% confidence interval
FIGURE 3Forest plot of proportion of wounds closed comparing ORC/collagen dressings and standard dressing use. Each study is displayed with the standard difference of the means and standard error and 95% confidence interval
FIGURE 4Forest plot of percent area reduction comparing oxidised regenerated cellulose (ORC)/collagen dressings and standard dressing use. Each study is displayed with the standard difference of the means and standard error, and 95% confidence interval
FIGURE 5Forest plot of area reduction comparing ORC/collagen dressing and standard dressing use. Each study is displayed with the standard difference of the means and standard error
FIGURE 6Estimated MMP‐2 concentrations by study. MMP‐2 concentrations reported as ng/mL (A) and pg/mL/mg (B) are shown. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05
FIGURE 7Estimated elastase concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05
FIGURE 8Estimated plasmin concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05
FIGURE 9Estimated gelatinase concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05
Adverse events reported from studies included in the meta‐analysis
| Collagen/ORC N = 1224 | Control N = 443 | |
|---|---|---|
| Number of subjects experiencing an AE | 87 (7.1%) | 79 (17.8%) |
| Number of AEs occurring by type | ||
| Allergic reaction | 5 (0.4%) | 5 (1.1%) |
| Erythema | 2 (0.16%) | 3 (0.68%) |
| Excessive exudate | 3 (0.24%) | 4 (0.90%) |
| Hyper granulation | 1 (0.08%) | 4 (0.90%) |
| Infection | 14 (1.1%) | 12 (2.7%) |
| Inflammation | 2 (0.16%) | 7 (1.6%) |
| Itching/pruritus | 3 (0.24%) | 0 |
| Pain | 18 (1.5%) | 7 (1.6%) |
| Perilesional skin irritation | 8 (0.65%) | 7 (1.6%) |
| Unspecified AE type | 44 (3.6%) | 49 (11.1%) |
| Serious AE | 25 (2.0%) | 35 (7.9%) |
| Death | 2 (0.16%) | 6 (1.4%) |
| Unspecified | 23 (1.9%) | 29 (6.5%) |
Abbreviation: AE, adverse event; ORC, oxidised regenerated cellulose.
Patients may experience more than one event.
Death was not related to treatment.